Neuphoria Therapeutics (NEUP) Free Cash Flow (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Free Cash Flow of -$3.4 million for Q1 2026, down 129.69% year-over-year from $11.5 million in Q1 2025, and up 46.88% quarter-over-quarter from -$6.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Free Cash Flow (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Free Cash Flow for 4 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 129.69% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$17.2 million (down 2734.23% YoY), while the FY2025 annual figure was $100000.0, up 100.68% from the prior year.
- Free Cash Flow grew to -$3.4 million in Q1 2026 per NEUP's latest filing, from -$6.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $11.5 million in Q1 2025 and bottomed at -$6.4 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$2.6 million across 4 years, with a median of -$3.6 million in 2025.
- Annual changes were most pronounced in 2025 — Free Cash Flow surged 447.59% — and 2026, when it tumbled 129.69%.
- Neuphoria Therapeutics' Free Cash Flow stood at -$3.9 million in 2023, then gained by 14.88% to -$3.4 million in 2024, then sank by 90.58% to -$6.4 million in 2025, then surged by 46.88% to -$3.4 million in 2026.
- Business Quant data shows NEUP's Free Cash Flow at -$3.4 million in Q1 2026, -$6.4 million in Q4 2025, and -$3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 292.04 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -95.09 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 477.44 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 433.84 Mn |
| 10 | Neuphoria Therapeutics | 21.37 Mn | 1.93 Mn | - | -3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -6.40 Mn |
| Dec 31, 2025 | -6.40 Mn |
| Sep 30, 2025 | -3.80 Mn |
| Sep 30, 2025 | -3.80 Mn |
| Jun 30, 2025 | -3.56 Mn |
| Jun 30, 2025 | -3.56 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Dec 31, 2023 | -3.95 Mn |